Date: 2014-12-16
Type of information: Grant
Company: Kymab (UK)
Investors: The Wellcome Trust (UK)
Amount:
Funding type: grant
Planned used: Kymab will use its human antibody discovery platform (Kymouse™) and antibody development expertise in partnership with academic groups from the Wellcome Trust Sanger Institute, the University of Westminster and Public Health England to rapidly discover and develop therapeutic antibodies that act against different strains of the Ebola virus.
Others: * On December 16, 2014, Kymab announced that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola. Kymab’s research originated five years ago at the Wellcome Trust Sanger Institute. Kymab’s transgenic human antibody platform (Kymouse™) enables it to discover and develop fully human, monoclonal antibody drugs, including a current focus on treatments for cancer, immune system diseases and infectious diseases. Founded in 2009, Kymab has raised over $70m of equity financing from the Wellcome Trust and the Bill & Melinda Gates Foundation.
Therapeutic area: Infectious diseases
